CHARLESTON, SC – DelRicht Research is proud to recognize Dr. E. Marshall Newton and the Charleston research team for achieving early, study-defining milestones in a Phase 2b clinical trial evaluating a novel treatment for hypertension.

Through focused coordination and operational preparedness, the site achieved first site activated and first patient screened, reaching screening just one day after activation and completing activation 27 days from award. These benchmarks reflect a high level of readiness and helped establish early momentum for the study as a whole.

Early execution of this caliber is especially meaningful in cardiovascular research, where protocol complexity, patient safety considerations, and enrollment logistics demand precision from the very start.

The Importance of Timely Execution in Hypertension Research

Hypertension remains one of the most prevalent chronic conditions globally and a leading risk factor for cardiovascular disease, stroke, and renal complications. Despite the availability of existing therapies, many patients continue to experience uncontrolled blood pressure due to limited efficacy, tolerability issues, or adherence challenges.

As a result, continued innovation in hypertension treatment is essential. Phase 2b trials play a critical role in this development pathway, refining dose selection, confirming efficacy signals, and informing late-stage study design. Delays at this stage can have downstream effects on development timelines, resource planning, and ultimately patient access to new therapies.

Metrics such as award-to-activation timelines and activation-to-screen speed are increasingly used by sponsors and CROs as indicators of site readiness and operational strength. Charleston’s performance demonstrates how proactive planning and experienced execution can meaningfully support trial velocity without compromising quality.

Leadership and Operational Excellence in Charleston

Dr. Newton brings deep clinical expertise in cardiovascular care and a strong commitment to advancing evidence-based medicine through research. His ability to integrate clinical trials into routine care environments allows patients to participate in research while maintaining continuity with trusted providers.

Operational leadership at the site was driven by Annelise Kauffman, Site Manager, whose coordination and attention to detail were instrumental in achieving these early milestones. From regulatory readiness and start-up planning to staff alignment and patient identification workflows, Annelise’s proactive approach ensured the team was fully prepared ahead of activation.

Together, the Charleston team exemplifies DelRicht’s physician-embedded research model, pairing clinical leadership with operational discipline to deliver predictable, high-quality performance.

Momentum That Supports Study Success

Achieving first activation and first patient screened is more than an operational achievement, it sets the tone for the entire study. Faster activation enables earlier data generation, supports informed development decisions, and helps sponsors and CRO partners maintain confidence in study timelines.

For patients, this momentum translates into earlier access to investigational therapies and the opportunity to contribute to advancing cardiovascular care.

At DelRicht Research, we are honored to collaborate with investigators like Dr. Newton and site teams like Charleston, whose leadership, preparation, and commitment help move clinical research forward. Their performance reinforces our mission of Moving Medicine Forward by delivering research that is efficient, patient-centered, and built for long-term impact.